Transthyretin Amyloid Cardiomyopathy

DBCOND0129905Cardiovascular DiseasesDisease and Non-Disease Concepts, Unclassified

Transthyretin Amyloid Cardiomyopathy is the indication for 2 drugs in DrugBank. It is covered by 3 curated, structured indications.

Also known as
TTR-CM · Transthyretin Cardiomyopathy (TTR-CM) · TTR Cardiomyopathy · Transthyretin (TTR) Amyloid Cardiomyopathy · Cardiac TTR Amyloidosis
Classified under
Indicated drugs

Resolves to

Vocabularies
SNOMED CT16573007MedDRA10002020UMLSC0268407

What you can answer from here — as of November 02, 2026

2Indicated drugsWith each drug's targets and mechanism
Listed above
3Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
46Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Drug reporting it as an adverse effectWith incidence where the label states it
Sign in

Which approved drugs for Transthyretin Amyloid Cardiomyopathy share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In